- Home
- CLDI vs SONN Comparison
CLDI vs SONN Comparison
Compare CLDI & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- SONN
- Stock Information
- Founded
- CLDI 2014
- SONN N/A
- Country
- CLDI United States
- SONN United States
- Employees
- CLDI N/A
- SONN N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- SONN Health Care
- Exchange
- CLDI Nasdaq
- SONN Nasdaq
- Market Cap
- CLDI 20.2M
- SONN 21.4M
- IPO Year
- CLDI N/A
- SONN N/A
- Fundamental
- Price
- CLDI $1.60
- SONN $5.54
- Analyst Decision
- CLDI
- SONN Strong Buy
- Analyst Count
- CLDI 0
- SONN 1
- Target Price
- CLDI N/A
- SONN $20.00
- AVG Volume (30 Days)
- CLDI 484.3K
- SONN 960.3K
- Earning Date
- CLDI 11-11-2025
- SONN 08-13-2025
- Dividend Yield
- CLDI N/A
- SONN N/A
- EPS Growth
- CLDI N/A
- SONN N/A
- EPS
- CLDI N/A
- SONN N/A
- Revenue
- CLDI N/A
- SONN $1,000,000.00
- Revenue This Year
- CLDI N/A
- SONN $5,376.22
- Revenue Next Year
- CLDI N/A
- SONN N/A
- P/E Ratio
- CLDI N/A
- SONN N/A
- Revenue Growth
- CLDI N/A
- SONN 1689.52
- 52 Week Low
- CLDI $1.51
- SONN $1.08
- 52 Week High
- CLDI $46.68
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- CLDI 30.60
- SONN 68.98
- Support Level
- CLDI $1.51
- SONN $2.71
- Resistance Level
- CLDI $1.68
- SONN $6.65
- Average True Range (ATR)
- CLDI 0.10
- SONN 0.67
- MACD
- CLDI 0.14
- SONN 0.28
- Stochastic Oscillator
- CLDI 22.97
- SONN 71.83
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.